Loading...
XSHE
002390
Market cap1.08bUSD
Dec 05, Last price  
3.93CNY
1D
-0.25%
1Q
7.67%
Jan 2017
-60.26%
IPO
-17.09%
Name

Guizhou Xinbang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002390 chart
P/E
75.35
P/S
1.27
EPS
0.05
Div Yield, %
1.53%
Shrs. gr., 5y
3.47%
Rev. gr., 5y
-1.95%
Revenues
6.03b
-6.63%
173,328,371217,753,605274,743,391336,685,856318,627,651361,864,803447,572,062569,487,9222,476,183,0594,179,756,0995,157,031,7756,002,471,0306,580,278,9186,655,063,5775,845,621,5256,471,866,3346,350,025,8276,460,841,3146,032,262,000
Net income
101m
-64.70%
17,450,89829,911,23833,613,68646,416,22737,757,39346,078,75347,828,99040,237,319144,770,445174,379,440246,012,798319,383,5010236,301,518173,521,475373,955,063224,374,022287,232,798101,382,000
CFO
635m
-19.69%
032,485,80024,860,89241,753,1232,500,7310000217,402,1650201,742,9490886,327,517742,111,911457,971,988590,796,585790,618,030634,969,000
Dividend
May 17, 20240.06 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.
IPO date
Apr 16, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT